Toggle Main Menu Toggle Search

Open Access padlockePrints

Intravenous Thrombolysis with Tenecteplase for the Treatment of Acute Ischemic Stroke

Lookup NU author(s): Dimitrios Mavridis, Dr Anand Dixit


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


© 2022 American Neurological Association. Objective: Intravenous thrombolysis (IVT) with tenecteplase has been associated with better clinical outcomes in acute ischemic stroke (AIS) patients with confirmed large vessel occlusions compared to IVT with alteplase. However, the utility of tenecteplase for the treatment of all AIS patients eligible for IVT has not been established. Methods: We compared the safety and efficacy of tenecteplase versus alteplase in AIS patients by analyzing propensity score matched data from 20 centers participating in the Safe Implementation of Treatments in Stroke–International Stroke Thrombolysis Register. Patients receiving IVT with tenecteplase were matched with up to 3 patients receiving alteplase from the same center. The primary outcome of interest was the distribution of 3-month functional outcomes. Secondary outcomes included the rates of patients with symptomatic intracranial hemorrhage (SICH) in the first 24 hours, excellent (modified Rankin Scale [mRS] score = 0–1) or good (mRS score = 0–2) functional outcome, and all-cause mortality at 3 months. Results: A total of 331 tenecteplase-treated AIS patients were matched to 797 patients treated with alteplase (median age = 70 years, 43.9% women, median National Institutes of Health Stroke Scale score = 11, interquartile range = 6–17). Patients treated with tenecteplase had better 3-month functional outcomes (common odds ratio [OR] = 1.54, 95% confidence interval [CI] = 1.18–2.00) with higher odds of good functional outcome (OR = 2.00, 95% CI = 1.45–2.77) and a lower likelihood of all-cause mortality (OR = 0.43, 95% CI = 0.27–0.67) at 3 months, compared to alteplase-treated patients. No difference was found in the likelihood of the 3-month excellent functional outcomes (OR = 1.31, 95% CI = 0.96–1.78) and 24-hour SICH (1.0% vs 1.3%, OR = 0.72, 95% CI = 0.20–2.64). Interpretation: IVT with tenecteplase was associated with better 3-month clinical outcomes compared to IVT with alteplase in AIS patients, with no increased risk of symptomatic intracranial bleeding. ANN NEUROL 2022.

Publication metadata

Author(s): Tsivgoulis G, Katsanos AH, Christogiannis C, Faouzi B, Mavridis D, Dixit AK, Palaiodimou L, Khurana D, Petruzzellis M, Psychogios K, Macleod MJ, Ahmed N

Publication type: Article

Publication status: Published

Journal: Annals of Neurology

Year: 2022

Online publication date: 17/06/2022

Acceptance date: 10/06/2022

ISSN (print): 0364-5134

ISSN (electronic): 1531-8249

Publisher: John Wiley and Sons Inc.


DOI: 10.1002/ana.26445

PubMed id: 35713213


Altmetrics provided by Altmetric